Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Economic information and modeling report

Modeling overview

16 evidence topics · 12 sources

Summary

No economic model, cost-effectiveness analysis, budget impact analysis, or health technology assessment of lonimecgene renparvovec (TSHA-102) was identified, and Taysha Gene Therapies has announced no price. Taysha estimates an addressable population of 15,000 to 20,000 patients with typical Rett syndrome caused by a pathogenic or likely pathogenic MECP2 mutation in the United States, the European Union, and the United Kingdom. In its second quarter 2026 results announcement, the company reported completed payer research in which TSHA-102 was viewed as a high-value therapy, with durable functional benefit as the key value determinant; its annual report states that the reimbursement structure of other companies' approved gene therapies could affect the anticipated reimbursement structure of its own products.

Trofinetide (DAYBUE) was approved by the FDA in March 2023 for the treatment of Rett syndrome. Acadia stated a list price of $21.10 per mL, or an estimated average net realized cost to payers of about $375,000 per year. Net product sales of DAYBUE were $177.2 million in 2023, $348.4 million in 2024, and $391.4 million in 2025. In a real-world analysis, 766 of 2,950 eligible individuals (26.0%) initiated trofinetide in the early post-approval period.

Canada's Drug Agency (CDA-AMC) appraised the sponsor's cost-effectiveness and budget impact analyses for trofinetide, and amounts below are those reported in that review. The sponsor's Markov cost-utility model, with 4 health states defined by Rett Syndrome Behaviour Questionnaire (RSBQ) score plus death and a lifetime horizon of 79.1 years, produced an incremental cost-effectiveness ratio of $5,864,321 per quality-adjusted life-year (QALY) gained (incremental costs $3,386,675; incremental QALYs 0.578), and a price reduction of more than 98% would be required to meet a threshold of $100,000 per QALY gained. Health state utilities, from a discrete choice experiment commissioned to develop utility-based scoring weights for the RSBQ, ranged from 0.6409 (mild to moderate) to 0.2160 (very severe). The sponsor's budget impact analysis, from the perspective of the pan-Canadian drug plans, assumed 95, 21, and 22 patients would start publicly reimbursed trofinetide in years 1, 2, and 3; the CDA-AMC reanalysis estimated a 3-year incremental budgetary cost of $166,461,725, with scenario analyses up to $333 million, and CDA-AMC recommended that trofinetide not be reimbursed by public drug plans. A systematic literature review screened 221 unique citations for pharmacoeconomic models and found no eligible publication.

Published economic model of TSHA-102

No evidence found.

Cost-effectiveness or budget impact analysis of TSHA-102

No evidence found.

Health technology assessment of TSHA-102

No evidence found.

Announced price or pricing guidance for TSHA-102

No evidence found.

Trofinetide cost-utility model submitted to Canada's Drug Agency: structure and inputs

“The sponsor submitted a cost-utility analysis assessing the cost-effectiveness of trofinetide plus BSC compared with BSC alone for the treatment of Rett syndrome in adults and pediatric patients aged 2 years and older and weighing at least 9 kg, which aligns with the proposed reimbursement request.” (opens the source at this quote in a new tab)

“The analyses were conducted from both the public health care payer and societal perspectives. The time horizon in the base case was a lifetime (79.1 years), and there was a 1.5% annual discount rate for costs and effectiveness.” (opens the source at this quote in a new tab)

“The sponsor submitted a Markov model with 5 distinct and mutually exclusive health states. Four health states were based on the RSBQ scores: mild to moderate (0 to 25), moderate to severe (26 to 50), severe (51 to 75), and very severe (76 to 90); and dead (Figure 1 in Appendix 3).” (opens the source at this quote in a new tab)

“The proportion of patients who discontinued treatment in the first year was approximately 48%, and discontinuation was assumed to be approximately 10% per year for year 2 and beyond.” (opens the source at this quote in a new tab)

“The 12-week (1 model cycle) cost of trofinetide in the model was $84,479 to $211,797 in cycle 1 with titration, and $102,399 to $255,996 in subsequent cycles; annual cost is $455,251 to $1,113,127 (up to 40 kg), assuming zero wastage.” (opens the source at this quote in a new tab)

“Health care resource use costs were estimated based on published literature.8,9 It was assumed that health care resource use was the same for each treatment arm and every health state.” (opens the source at this quote in a new tab)

“To estimate the indirect costs (caregiver time and productivity loss), caregiving time for spinal muscular atrophy was used as a proxy based on a study conducted by Aranda-Reneo et al.11 of informal caregivers in 4 European countries (France, Germany, Spain, and the UK).” (opens the source at this quote in a new tab)

Trofinetide cost-utility model submitted to Canada's Drug Agency: results and appraisal

Trofinetide budget impact analysis submitted to Canada's Drug Agency